Mehalick David 4

4 · Coeptis Therapeutics Holdings, Inc. · Filed Jan 31, 2023

Form 4

Period: 2023-01-27

DirectorCEO and President10% Owner

Transactions

Award
Incentive Stock Options (right to buy)
2023-01-27+250,000→ 250,000 total
Exercise: $1.76→ Common Stock (250,000 underlying)
Award
Non-qualified Stock Options (right to buy)
2023-01-27+375,000→ 375,000 total
Exercise: $1.60→ Common Stock (375,000 underlying)

Footnotes (10)

[F1]On January 27, 2023, the reporting person received a grant of 375,000 stock options, as non-qualified options, under the 2022 equity incentive plan.
[F10]Following the exercise of options under both reported transactions, the reporting person will have a total of 625,000 derivative securities beneficially owned.
[F2]On January 27, 2023, the reporting person received a grant of 250,000 incentive stock options, under the 2022 equity incentive plan.
[F3]Options will vest over 4 years, with the first 25% vesting on 12/31/23, and the balance vesting in equal quarterly installments over the succeeding three years, with the final options vesting on 12/31/26.
[F4]Options will vest over 4 years, with the first 25% vesting on 12/31/23, and the balance vesting in equal quarterly installments over the succeeding three years, with the final options vesting on 12/31/26.
[F5]The exercise price is the FMV of the shares, which is equal to the Company's stock price on the Nasdaq Global Market on the day of grant.
[F6]The exercise price is equal to 110% of the FMV of the shares on the day of grant.
[F7]Expiration date is ten years from the day of grant
[F8]Expiration date is five years from the day of grant, as the reporting person is a 10% owner and the options are incentive stock options.
[F9]Following the exercise of options under both reported transactions, the reporting person will have a total of 625,000 derivative securities beneficially owned.

Documents

1 file